Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis

References

• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for Diagnosis, Management, and Prevention of COPD2007 Accessed onJanuary 10, 2009 Available from: http://www.goldcopd.com/download.asp?intId=50215
   Google Scholar
• American Thoracic SocietyStandards for the diagnosis and care of patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med1995152S771217582322
   PubMed Web of Science ®Google Scholar
• WedzichaJAExacerbations: etiology and pathophysiologic mechanismsChest200212Suppl 5136S141S12010842
   PubMed Web of Science ®Google Scholar
• Van WeelCChronic diseases in general practice: the longitudinal dimensionEur J Gen Pract199621721
   Google Scholar
• MurphyTFSethiSBacterial infection in chronic obstructive pulmonary diseaseAm Rev Respir Dis1992146106710831416398
   PubMed Web of Science ®Google Scholar
• WilsonRA vicious circle hypothesis operating during infective exacerbations of chronic bronchitisMonaldi Arch Chest Dis19944921591648049702
   PubMedGoogle Scholar
• SethiSMurphyTFAcute exacerbations of chronic bronchitis: new developments concerning microbiology and pathophysiology – impact on approaches to risk stratification and therapyInfect Dis Clin North Am20041886188215555829
   PubMed Web of Science ®Google Scholar
• MartinezFJCurtisJLProcalcitonin-guided antibiotic therapy in COPD exacerbations: closer but not quite thereChest2007131191917218551
   PubMed Web of Science ®Google Scholar
• AnthonisenNRManfredaJWarrenCPWHershfieldESHardingGKMNelsonNAAntibiotic therapy in exacerbations of chronic obstructive pulmonary diseaseAnn Intern Med19871061962043492164
   PubMed Web of Science ®Google Scholar
• BalterMSLa ForgeJLowDECanadian guidelines for the management of acute exacerbations of chronic bronchitis: executive summaryCan Respir J20031024825812945001
   PubMedGoogle Scholar
• StephenBBlainePCRichardCAcute exacerbation of chronic bronchitis: A primary care consensus guidelineAm J Manage Care200410689696
   Web of Science ®Google Scholar
• FlahertyKRSainSFendrickAMMartinezFJThe spectrum of acute bronchitis: using baseline factors to guide empirical therapyPostgrad Med2001109394711272693
   PubMed Web of Science ®Google Scholar
• SethiSInfectious exacerbations of chronic bronchitis: diagnosis and managementJ Antimicrob Chemother199943Suppl A971010225579
   PubMed Web of Science ®Google Scholar
• KahnJBKhashabMAmbruzsMStudy entry microbiology in patients with acute bacterial exacerbation of chronic bronchitis in a clinical trial stratifying by disease severityCurr Med Res Opin20072311717261234
   PubMed Web of Science ®Google Scholar
• SethiSInfectious etiology of acute exacerbations of chronic bronchitisChest20001175 Suppl 2380S3805S10843981
   PubMed Web of Science ®Google Scholar
• AnzuetoANiedermanMSPearleJRestrepoMIHeyderAChoudhriSHCommunity-Acquired Pneumonia Recovery in the Elderly Study GroupCommunity-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapyClin Infect Dis200642738116323095
   PubMed Web of Science ®Google Scholar
• WelteTPetermannWSchürmannDBauerTTReimnitzPMOXI-RAPID Study GroupTreatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapyClin Infect Dis20054112169770516288390
   PubMed Web of Science ®Google Scholar
• FernandoJMAnzuetoAAppropriate outpatient treatment of acute bacterial exacerbation of chronic bronchitisAm J Med2005118Suppl 7A39S44S15993676
   PubMedGoogle Scholar
• TangPGreenKMcGeerAFluoroquinolone resistance in Streptococcus pneumoniae in Canada – are we currently surveying just the tip of the iceberg?Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego)Washington, DCAmerican Society for Microbiology2002110
   Google Scholar
• KellyLMultidrug-resistant pneumococci isolated in the US: 1997–2001 TRUST surveillance [abstract]Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago)Washington, DCAmerican Society for Microbiology2001142
   Google Scholar
• NiedermanMSGuidelines for the management of community-acquired pneumonia. Current recommendations and antibiotic selection issuesMed Clin North Am2001851493150911680113
   PubMed Web of Science ®Google Scholar
• DoernGVAntimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United StatesClin Infect Dis200133Suppl 3S18719211524718
   PubMed Web of Science ®Google Scholar
• KaatzGWSeoSMMechanism of fluoroquinolone resistance in genetically related strains of Staphylococcus aureusAntimicrob Agents Chemother199712273327379420048
   PubMed Web of Science ®Google Scholar
• LaPlanteKLRybakMJRsujiBLodiseTPKaatzGWFluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacinAntimicrob Agents Chemother20075141315132017296740
   PubMed Web of Science ®Google Scholar
• SmithHJHobanDJZhanelGGDual activity of fluoroquino-lones against Streptococcus pneumoniae: the facts behind the claimsJ Antimicrob Chemorther200249893895
   PubMed Web of Science ®Google Scholar
• De AzavedoJCSDuncanCLKilurnLRelative potential for selection of quinolone-resistance-determining-region mutations in Streptococcus pneumoniae by gemifloxacin, gatifloxacin and moxi-floxacinJ Chemother200618437337817024792
   PubMed Web of Science ®Google Scholar
• AppelbaumPCGillespieSHBurleyCJTillotsonGSAntimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacinInt J Antimicrob Agents20042353354615194123
   PubMed Web of Science ®Google Scholar
• YooBKTrillerDMYongCSLodiseTPGemifloxacin: a new fluoroquinolone approved for treatment of respiratory infectionsAnn Pharmacother2004387812261235
   Web of Science ®Google Scholar
• RussoRBelloJAChristopherLLack of effect of high-fat meal on the bioavailability of garenoxacin oral suspension in healthy subjectsChicago, ILAmerican Society of Hospital Pharmacists (ASHP) Midyear Clinical Meeting2002
   Google Scholar
• GajjarDASukoneckSCBelloAGeZChristopherLGraselaDMEffect of a high-fat meal on the pharmacokinetics of the des-F(6)-quinolone BMS-284756Pharmacotherapy20022216016511837554
   PubMed Web of Science ®Google Scholar
• ZhanelGGFontaineSAdamHA review of new fluoroquinolones – focus on their use in respiratory tract infectionsTreat Respir Med20065643746517154673
   PubMedGoogle Scholar
• SmithHJHobanDJZhanelGGMolecular characterization and mutatnt prevention concentration (MPC) determination of single-step fluoroquinolone resistant mutants of SpneumoniaeChicago, IL41st Interscience Conference of Antimicrobial Agents and Chemotherapy20012225
   Google Scholar
• BlondeauJMBorsosSComparative minimum inhibitory concentration and mutant preveniton concentration of azithromycin, cefuroxime, gemifloxacin, moxifloxacin and telithromycin against clinical isolates of Haemophilus influenzaeMunich, Germany17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)2007 March 31–April 3 Abstract P-747
   Google Scholar
• ZhanelGGEnnnisKVercaigneLA critical review of the fluoroquinolones: focus on respiratory infectionsDrugs2002621135911790155
   PubMed Web of Science ®Google Scholar
• TranJQBallowCHForrestAComparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variablesJ Antimicrob Chemother20004591710719007
   PubMed Web of Science ®Google Scholar
• KingAMayJGrenchGPhillipsIComparative in vitro activity of gemifloxacinJ Antimicrob Agents200321574577
   Web of Science ®Google Scholar
• ThomasKSForrestABhavnaniSMPharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapyAntimicrob Agents Chemother1998425215279517926
   PubMed Web of Science ®Google Scholar
• DaviesTAKellyLMPankushGACreditoKLJacobsMRAppelbaumPCAntipneumococcal activities of gemifloxacin compared to those of nine other agentsAntimicrob Agents Chemother20024626727411796329
   PubMed Web of Science ®Google Scholar
• DaviesTAKellyLMHoellmanDBActivities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalisAntimicrob Agents Chemother20004463363910681330
   PubMed Web of Science ®Google Scholar
• DrlicaKA strategy for fighting antibiotic resistanceASM News2001672733
   Google Scholar
• OwensRDBhavnaniSMAmbrosePGAssessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniaeDiagn Microbiol Infect Dis200551454915629228
   PubMed Web of Science ®Google Scholar
• PereyreSRenaudinHBébéarCBébéarCMIn vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmasAntimicrob Agents Chemother20044883165316815273141
   PubMed Web of Science ®Google Scholar
• PankuchGALinGAppelbaumPCActivity of five quinolones, three macrolides and telithromycin against 12 Haemophilus influenzae strains with different resistance phenotypesClin Microbiol Infect200511121040104416307562
   PubMed Web of Science ®Google Scholar
• BalkhyHHMemishZAShibiAIn vitro activity of quinolones against S. pneumoniae, H. influenzae and M. catarrhalis in Saudi ArabiaEast Mediterr Health J200511123644
   Google Scholar
• De AzavedoJCSDuncanCLKilurnLRelative potential for selection of quinolone-resistance-determining-region mutations in Streptococcus pneumoniae by gemifloxacin, gatifloxacin and moxi-floxacinJ Chemother200618437337817024792
   PubMed Web of Science ®Google Scholar
• LaPlanteKLRybakMJTsujiBLodiseTPKaatzGWFluoro-quinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacinAntimicrob Agents Chemother20075141315132017296740
   PubMed Web of Science ®Google Scholar
• BerryVPageRSatterfieldJSingleyCStraubRWoodnuttGComparative in vivo acitivity of gemifloxacin in a rat model of respiratory tract infectionJ Antimicrob Chemother200045Suppl 1798510824037
   PubMed Web of Science ®Google Scholar
• BastDDresserLDuncanCLShort-course therapy of gemifloxa-cin effective against pneumococcal pneumonia in miceJ Chemother2006184551
   Web of Science ®Google Scholar
• WilsonRLanganCBallPGemifloxacin 207 Clinical Study GroupOral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitisRespir Med20039724224912645831
   PubMed Web of Science ®Google Scholar
• WilsonRSchentagKKBallPMandellL068 Study GroupA comparison of gemifloxacin and clarithromycin in acute exacerbation of chronic bronchitis and long-term clinical outcomesClin Ther20022463965212017408
   PubMed Web of Science ®Google Scholar
• FileTSchlemmerBGarauJLodeHLynchSYoungCGemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study groupJ Chemother200012431432510949981
   PubMed Web of Science ®Google Scholar
• BallPWilsonRMandellLBrownJHenkelT069 Clinical Study GroupEfficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomized, double-blind comparison with trovafloxacinJ Chemother20011328829811450888
   PubMed Web of Science ®Google Scholar
• BallPFileTMJrTwynholmMHenkelT061 Study GroupEffi-cacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infectionsInt J Antimicrob Agents200118192711463522
   PubMed Web of Science ®Google Scholar
• SethiSFogartyCFulambarkerAA randomized double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitisRespir Med200498869770715303633
   PubMed Web of Science ®Google Scholar
• JadadARMooreRACarrollDAssessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials19961711128721797
   PubMedGoogle Scholar
• FrothinghamRRates of torsades de pointes associated with cip-rofloxacin, ofloxacin, levofloxacin, gatifloxacin and moxifloxacinPharmacotherapy2001211468147211765299
   PubMed Web of Science ®Google Scholar
• OwensRCQT prolongation with antimicrobial agents: understanding the significanceDrugs200464101091112415139788
   PubMed Web of Science ®Google Scholar
• Arizona CERT: Center for Education and Research on TherapeuticsQT drug lists by risk groups April 152009 Accessed onMay 11, 2009 Available from: http://www.azcert.org/medical-pros/drug-lists/drug-lists.cfm
   Google Scholar
• FalagasMERafailidisPIRosmarakisESArrhythmias associated with fluoroquinolone therapyInt J Antimicrob Agents20072937437917241772
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA Black Box Warning for fluoroquinolones July 82008 Accessed onMay 11, 2009 Available from: http://www.fda.gov/cder/drug/InfoSheets/HCP/fluoroquino-lonesHCP.htm
   Google Scholar
• HalpernMTPalmerCSZodetMKirschJCost-effectiveness of gemifloxacin: results from the GLOBE studyAm J Health Syst Pharm2002591357136512132563
   PubMed Web of Science ®Google Scholar